ASSET PLANNING Exits Full Stake in Pfizer Worth $2.7 Million

ASSET PLANNING SERVICES INC /LA/ /ADV has fully divested its entire 109,630-share position in Pfizer, valued at an estimated $2.66 million, according to an October 16, 2025 SEC filing. This exit, which previously constituted 1.2% of the fund's AUM, follows Pfizer's 8.5% year-to-date decline and significant underperformance against the S&P 500, reflecting ongoing post-pandemic challenges. The move suggests a strategic shift by the fund towards growth-oriented sectors, as its top holdings are now concentrated in technology and financial leaders like NVIDIA and Microsoft.

Analysis

ASSET PLANNING SERVICES INC /LA/ /ADV fully divested its entire 109,630-share position in Pfizer (PFE) during Q3 2025, an estimated $2.66 million trade, as disclosed in an October 16, 2025 SEC filing. This move eliminated a holding that previously constituted 1.2% of the fund's assets under management. The divestment occurred amidst Pfizer's significant underperformance, with shares down 8.5% year-to-date and trailing the S&P 500 by 21 percentage points.

This complete exit signals a strategic reallocation by the fund, shifting capital towards growth-oriented sectors. The fund's top holdings now heavily feature technology and financial leaders like NVIDIA (19.9% AUM), Microsoft (10.6% AUM), and JPMorgan Chase (5.6% AUM). Pfizer continues to face headwinds from declining COVID-related revenues and intense competition in key therapeutic areas post-pandemic.

Despite the fund's divestment, Pfizer maintains a substantial 7.05% dividend yield and a robust drug pipeline. While the current market sentiment towards PFE is negative (-0.6 per-ticker sentiment), its established brands and broad international reach provide a competitive edge. This presents a nuanced view for long-term investors who might consider the current weakness an entry opportunity.

Key Decisions for Investors

• Investors should evaluate their portfolio allocation for alignment with the observed institutional shift towards growth-oriented technology and financial sectors, as evidenced by ASSET PLANNING SERVICES INC's rebalancing.
• Re-evaluate Pfizer's long-term investment thesis by weighing its current valuation ($24.27, -8.5% YTD) and 7.05% dividend yield against ongoing challenges from post-pandemic revenue declines and competitive pressures.
• Monitor Pfizer's strategic initiatives to diversify revenue streams and navigate intense competition in its biopharmaceutical segments, as these factors will be critical for future performance and shareholder returns.